Last reviewed · How we verify
CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM is a drug. It is currently FDA-approved (first approved 1984).
At a glance
| Generic name | CEFTRIAXONE SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
Common side effects
- Elevations of alanine aminotransferase (ALT)
- Elevations of aspartate aminotransferase (AST)
- Diarrhea/loose stools
- Leukopenia
- Rash
- Elevations of BUN
- Pain, induration and tenderness
- Granulocytopenia
- Injection site pain
- Blood creatinine increased
- Coagulopathy
- Genital fungal infection
Serious adverse events
- Eosinophilia
- Thrombocytosis
- Anaphylaxis
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis (Lyell's syndrome)
- Seizures
- Agranulocytosis
- Kernicterus
- Acute renal failure
- Pancreatitis
Key clinical trials
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- PK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEFTRIAXONE SODIUM CI brief — competitive landscape report
- CEFTRIAXONE SODIUM updates RSS · CI watch RSS
Frequently asked questions about CEFTRIAXONE SODIUM
What is CEFTRIAXONE SODIUM?
CEFTRIAXONE SODIUM is a Small molecule drug.
When was CEFTRIAXONE SODIUM approved?
CEFTRIAXONE SODIUM was first approved on 1984.
What development phase is CEFTRIAXONE SODIUM in?
CEFTRIAXONE SODIUM is FDA-approved (marketed).
What are the side effects of CEFTRIAXONE SODIUM?
Common side effects of CEFTRIAXONE SODIUM include Elevations of alanine aminotransferase (ALT), Elevations of aspartate aminotransferase (AST), Diarrhea/loose stools, Leukopenia, Rash, Elevations of BUN. Serious adverse events: Eosinophilia, Thrombocytosis, Anaphylaxis, Stevens-Johnson syndrome.
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing